MedTrace Logo

Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell

NCT02420392 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-04-21

No results posted yet for this study

Summary

To investigate the effect of dapagliflozin on the incretin sensitivity of the pancreatic beta cell.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Dapagliflozin

8 weeks treatment of dapagliflozin added to the type 2 diabetes patients with unsufficiently controlled with metformin or sulfonylurea

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Young Min Cho, M.D., Ph.D. · Seoul National University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02420392 on ClinicalTrials.gov